Authors: Rosamond Lougheed, John Turnbull
DOI: 10.1371/journal.pone.0023141
Abstract Summary
Methylene blue, a well-established drug with promising theoretical benefits for ALS, showed limited efficacy in mice carrying the SOD1 G93A mutation. While treated mice spent more time in earlier disease stages and females showed modest delays in symptom onset, overall survival wasn’t significantly improved, suggesting methylene blue may not be an effective ALS treatment despite its strong safety profile.
Why Brain? ðŸ§
Methylene blue showed no significant benefit for ALS in mice despite promising theory, though treated mice spent more time in less severe disease stages, suggesting limited therapeutic potential.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
